We claim:

1. A compound of the formula:



wherein X is selected from the group comprising O and S;
wherein A_1 and A_2 are individually selected from the group comprising O, S and N;
wherein G_1 and G_3 are C_{1-4} alkyl chains;
wherein G_5 is a C_{0-4} alkyl chain;
wherein G_2 is selected from the group comprising:



or H,

wherein A_3 and A_4 are individually selected from the group comprising O, N, or S, and G_8 is a C_{1-4} alkyl chain;
wherein G_4 is a C_{5-8} aryl, a C_{5-8} arylsulfonylamino, an C_{5-8} arylamino; and
wherein G_6 and G_7 are individually selected from the group comprising H, F, Cl, I, Br and a C_{1-4} alkyl.

2. The compound of claim 1, wherein X is S.

3. The compound of claim 1, wherein X is 0.

4. The compound of claim 1, wherein A_1 is N.

5. The compound of claim 1, wherein A_1 is O.

6. The compound of claim 1, wherein A_2 is N.

7. The compound of claim 1, wherein A_2 is O.

8. The compound of claim 1, wherein G_1 is a C_1 alkyl.

9. The compound of claim 1, wherein G1 is $-(CH_2)_0-$.

10. The compound of claim 1, wherein G_1 is a C_2 alkyl.

11. The compound of claim 1, wherein G_1 is a C_3 alkyl.

12. The compound of claim 1, wherein G_3 is a C_1 alkyl.

13. The compound of claim 1, wherein G_3 is a C_2 alkyl.

14. The compound of claim 1, wherein G_5 is a C_1 alkyl.

15. The compound of claim 1, wherein G_5 is a C_2 alkyl.

16. The compound of claim 1, wherein G_2 is represented by the formula:



or H,

wherein A_3 is selected from the group comprising O, S and N and A_4 is N.

17. The compound of claim 1, wherein G_2 is represented by the formula:



or H,

wherein A_3 and A_4 are individually selected from the group comprising N or O and G_8 is a C_{2-3} alkyl chain.

18. The compound of claim 1, wherein -N-G_2 forms a guanidino containing moiety.

19. The compound of claim 1, wherein -N-G_2 forms a urea containing moiety.

20. The compound of claim 1, wherein -N-G_2 forms a cyclic guanidino containing moiety.

21. The compound of claim 1, wherein -N-G_2 forms a cyclic urea containing moiety.

22. The compound of claim 1, wherein G_4 is phenylsulfonylamino.

23. The compound of claim 1, wherein G_4 is phenyl.

24. The compound of claim 1, wherein G_6 and G_7 are halogens.

25. The compound of claim 1, wherein G_6 and G_7 are the same.

26. The compound of claim 1, wherein G_6 or G_7 are F.

27. The compound of claim 1 further represented by the formula:



wherein X is selected from the group comprising O and S;

A_1 and A_2 are individually selected from the group comprising O, S and N;
G_1 and G_3 are C_{1-4} alkyl chains;
G_2 is selected from the group comprising:



wherein A_3 and A_4 are individually selected from the group comprising O, N, or S, and G_8 is a C_{1-4} alkyl chain;
wherein G_4 is a C_{5-8} aryl, a C_{5-8} arylsulfonylamino, or a C_{5-8} arylamino; and
wherein G_6 and G_7 are individually selected from the group comprising H, F, Cl, I, Br and a C_{1-4} alkyl.

28. The compound of claim 26, wherein X is S.

29. The compound of claim 26, wherein X is O.

30. The compound of claim 26, wherein G_1 is a C_1 alkyl.

31. The compound of claim 26, wherein G_1 is a C_2 alkyl.

32. The compound of claim 26, wherein G_3 is a C_1 alkyl.

33. The compound of claim 26, wherein G_3 is a C_2 alkyl.

34. The compound of claim 26, wherein G_2 is represented by the formula:



wherein A_3 is selected from the group comprising O, S and N and A_4 is N.

35. The compound of claim 26, wherein G_2 is represented by the formula:



or H,

wherein A_3 and A_4 are individually selected from the group comprising N or O and G_8 is a C_{2-3} alkyl chain.

36. The compound of claim 26, wherein -N-G_2 forms a guanidino containing moiety.

37. The compound of claim 26, wherein -N-G_2 forms a urea containing moiety.

38. The compound of claim 26, wherein -N-G_2 forms is a cyclic guanidino containing moiety.

39. The compound of claim 26, wherein -N-G_2 forms a cyclic urea containing moiety.

40. The compound of claim 26, wherein G_4 is phenylsulfonylamino.

41. The compound of claim 26, wherein G_4 is phenyl.

42. A method of treating cancer comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.

43. A method of treating a tumor comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.

44. A method of treating a solid tumor comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.

45. A method of treating metastasis comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.

46. A method of inhibiting angiogenesis comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.

47. A method of inhibiting fibronectin binding comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.

48. A method of inhibiting osteopontin binding comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.

49. A method of treating foot and mouth disease comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.

50. A method of treating osteoporosis comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.

51. A method of treating restenosis comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.

52. A method of treating ocular diseases comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.

53. A method of treating heart diseases comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.

54. A method of treating arthritis comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.

55. A method of treating diseases in which abnormal neovascularization occurs comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.

56. A method of inhibiting αv integrins comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.

57. A method of inhibiting $\alpha_v\beta_3$ integrin comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.

58. A pharmaceutical composition for treating cancer comprising a pharmaceutically effective amount of a compound of claim 1.

59. A pharmaceutical composition for treating tumor comprising a pharmaceutically effective amount of a compound of claim 1.

60. A pharmaceutical composition for treating solid tumor comprising a pharmaceutically effective amount of a compound of claim 1.

61. A pharmaceutical composition for treating metastasis comprising a pharmaceutically effective amount of a compound of claim 1.

62. A pharmaceutical composition for inhibiting angiogenesis comprising a pharmaceutically effective amount of a compound of claim 1.

63. A pharmaceutical composition for inhibiting fibronectin binding comprising a pharmaceutically effective amount of a compound of claim 1.

64. A pharmaceutical composition for inhibiting osteopontin binding comprising a pharmaceutically effective amount of a compound of claim 1.

65. A pharmaceutical composition for treating foot and mouth disease comprising a pharmaceutically effective amount of a compound of claim 1.

66. A pharmaceutical composition for treating osteoporosis comprising a pharmaceutically effective amount of a compound of claim 1.

67. A pharmaceutical composition for treating restenosis comprising a pharmaceutically effective amount of a compound of claim 1.

68. A pharmaceutical composition for treating ocular diseases comprising a pharmaceutically effective amount of a compound of claim 1.

69. A pharmaceutical composition for treating heart diseases comprising a pharmaceutically effective amount of a compound of claim 1.

70. A pharmaceutical composition for treating arthritis comprising a pharmaceutically effective amount of a compound of claim 1.

71. A pharmaceutical composition for treating diseases in which abnormal neovascularization occurs comprising a pharmaceutically effective amount of a compound of claim 1.

72. A pharmaceutical composition for inhibiting α_v integrins comprising a pharmaceutically effective amount of a compound of claim 1.

73. A pharmaceutical composition for inhibiting $\alpha_v\beta_3$ integrin comprising a pharmaceutically effective amount of a compound of claim 1.

74. A combination useful for the treatment of cancer comprising at least one compound of claim 1 with at least one other anticancer agent or antiangiogenic agent.

75. A combination useful for the treatment of cancer comprising at least one compound of claim 1 with at least one other anticancer agent selected from the group consisting of alkylating agents, antitumor antibiotics, antimetabolites, biological agents, hormonal agents, nitrogen mustard derivatives and plant alkaloids.